An Australian stem cell and regenerative medicine company

Board Of Directors

Dr Paul Wotton

Chairman

Dr. Wotton joined Cynata’s Board of Directors in June, 2016. He was previously President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) joining the company in July 2014 and managing it through a take-over by Astellas Pharma, Inc., in a US$379 million all cash transaction. Prior to Ocata, Dr. Wotton had served as President and CEO of Antares Pharma Inc. (NASDAQ: ATRS), since October, 2008. Prior to joining Antares, Dr. Wotton was the CEO of Topigen Pharmaceuticals and prior to Topigen, he was the Global Head of Business Development of SkyePharma PLC. Earlier in his career he held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr. Wotton is a member of the board of Vericel Corporation, a US company developing autologous cellular therapies and also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada. Dr. Wotton received his Ph.D. in pharmaceutical sciences from the University of Nottingham and an MBA from Kingston Business School. In 2014 he was named New Jersey EY Entrepreneur of the Year in Life Sciences.

Dr Ross Macdonald

Managing Director and Chief Executive Officer

Dr Macdonald has over 20 years’ experience and a track record of success in pharmaceutical and biotechnology businesses. His career history includes positions as Chief Executive Officer of Hatchtech Pty Ltd, Vice President of Business Development for Sinclair Pharmaceuticals Ltd, a UK-based specialty pharmaceuticals company, Vice President of Business Development for Connetics Corporation (Palo Alto, CA), and Vice President, Corporate Development for Stiefel Laboratories Inc, the largest independent dermatology company in the world and acquired by Glaxo Smith Kline in 2009 for £2.25b. Dr Macdonald has also served as Vice President of Research and Development of F H Faulding & Co Ltd and CEO of Living Cell Technologies Ltd.  His other positions have included non-executive director roles at iSonea Ltd, Telesso Technologies Ltd, Hatchtech Pty Ltd and Relevare Pharmaceuticals Ltd. Dr Macdonald currently serves as a member of the Investment Committee of UniSeed Management Pty Ltd. Dr Macdonald holds a PhD in Biochemistry, Monash University, a Graduate Diploma in Business Administration, Swinburne University, and he is a member of the Licensing Executives Society.

Dr Stewart Washer

Non-Executive Director

Stewart has 20 years of CEO and Board experience in medical technology, biotech and agrifood companies. In addition to his role as Executive Chairman at Cynata, he is also the Chairman of Orthocell Ltd, who culture tendon cells to repair damaged tendons and Chairman of Minomic International Ltd who have an accurate non-invasive test for prostate cancer.

Stewart was previously the CEO of Calzada Ltd (ASX:CZD), the founding CEO of Phylogica Ltd (ASX:PYC) and before this, he was CEO of Celentis and managed the commercialisation of intellectual property from AgResearch in New Zealand with 650 Scientists and $130m revenues. He was also a founder of a NZ$120m New Zealand based life science fund and Venture Partner with the Swiss based Inventages Nestlé Fund. He is currently Investment Director with Bioscience Managers.

Stewart has held a number of Board positions in the past as the Chairman of iSonea Ltd (ASX:ISN), Resonance Health Ltd (ASX:RHT) and Hatchtech Pty Ltd, a Director of iCeutica Pty Ltd, Immuron Ltd (ASX:IMC) and AusBiotech Ltd. He was also a Senator with Murdoch University and is currently the Chairman of Firefly Health.

Mr Peter Webse

Non-Executive Director/Company Secretary

Mr Webse has over 23 years’ company secretarial experience. He is the Managing Director of Platinum Corporate Secretariat Pty Ltd, a company specialising in providing company secretarial, corporate governance and corporate advisory services.

Dr Geoff Brooke

Board of Directors

Dr Brooke joined the Cynata Board in May 2019.  He founded GBS Venture Partners in 1996 and has more than 20 years’ venture capital experience. Geoff was formally President of Medvest Inc., a US-based early-stage venture capital group he founded with Johnson & Johnson. Geoff's experience includes company formation and acquisitions, as well as public listings on the NYSE, NASDAQ and ASX exchanges. He is a non-executive director of Acrux Limited (ASX:ACR), Chairman of Actinogen Medical Limited (ASX: ACW) and has been a founder, executive and director of private and public companies. From 2009 until 2015, he was an independent director of the Victoria Workcover Authority. Dr. Geoff Brooke is licensed in clinical medicine by the Medical Board of Victoria, Australia and his post-graduate work was in anaesthetics and intensive care. He earned his Bachelor of Medicine/Surgery from the University of Melbourne, Australia and a Masters of Business Administration from IMEDE (now IMD) in Lausanne, Switzerland.